FADD and hepatocellular carcinoma: Taken together, these results suggest that the sorafenib-oxaliplatin combination has a synergistic antitumor effect on AFP-expressing HCC cells and that the AFP-mediated HuR/Fas/FADD apoptotic cascade performs a direct role in this process.